跳至主要内容
临床试验/NL-OMON48415
NL-OMON48415
已完成
不适用

An exploratory study to biotype adult patients with unipolar depression using digital technologies - Digital biotyping of patients with unipolar depression

Centre for Human Drug Research0 个研究点目标入组 60 人待定

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Unipolar depression
发起方
Centre for Human Drug Research
入组人数
60
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
去年
研究类型
Observational non invasive

研究者

入排标准

入选标准

  • 1\. Written informed consent must be obtained before any assessment is performed.
  • 2\. Males and females, age 18 to 65 years (inclusive).
  • 3\. Body mass index (BMI) between 18 and 32 kg/m2\.
  • 4\. Primary diagnosis of moderate to severe major depressive disorder (MDD) without psychotic features or persistent depressive disorder (PDD)/dysthymia according to the DSM\-IV or DSM\-5, as diagnosed by the attending general practitioner, psychiatrist or clinical psychologist and confirmed with the Mini International Neuropsychiatric Interview (MINI) version 7\.0\.
  • 5\. Total MADRS\-SIGMA total score of \>22 at Screening.
  • 6\. Meeting one of the following conditions;
  • o no treatment with mono\-aminergic antidepressant drugs (SSRI, SNRI, mirtazapine, TCA, MAO\-I) and/or lithium for at least 2 weeks (6 weeks for fluoxetine) before Screening; or
  • o treatment with mono\-aminergic antidepressant drugs (SSRI, SNRI, mirtazapine, TCA, MAO\-I), with or without lithium, at a stable dose for at least 4 weeks prior to Screening (6 weeks for fluoxetine)
  • 7\. Must read and speak Dutch as a first or second language.
  • 8\. Able to comply with the study procedures, prohibitions and restrictions (drug and alcohol use) as specified in the protocol.

排除标准

  • 1\. Current or previously diagnosed psychotic disorder, bipolar disorder, mental retardation, cluster B personality disorder (i.e. borderline, antisocial, narcissistic or histrionic personality disorders).
  • 2\. Clinically significant suicidality within the past 6 months as demonstrated with the C\-SSRS or as judged by the investigator.
  • 3\. Use of sedative medication started within 2 weeks before Visit 1 and/or daily use of benzodiazepines with a dose equivalent of more than 10 mg Diazepam.
  • 4\. Foreseeable alterations in the dose of mono\-aminergic antidepressant drugs (SSRI, SNRI, mirtazapine, TCA, MAO\-I) and lithium during the course of the study.
  • 5\. Positive alcohol breath test or urine test for drugs of abuse at Screening (positive urine test for benzodiazepines is allowed) or a current diagnosis of substance use disorder (including alcohol but excluding nicotine), or previous substance use disorder (including alcohol but excluding nicotine) within the past 12 months according to DSM\-IV or DSM\-5\.
  • 6\. Evidence of any active or chronic disease or condition that could interfere with the conduct of the study.
  • 7\. Positive urine \*\-human chorionic gonadotropin (\*\-hCG) pregnancy test at Screening in women of childbearing potential.
  • 8\. Wearing a pacemaker or other internal medical device (e.g. Vagus nerve stimulation (VNS), Deep Brain Stimulation (DBS)).
  • 9\. Current enrollment in another study.;Healthy volunteers:
  • 1\. Current or previous clinically relevant history or family history of psychiatric disorders, neurological disorders or neurosurgery.

结局指标

主要结局

未指定

相似试验